Swisstrop 100 IU is indicated for long-term treatment of children with growth failure due to inadequate secretion of endogenous growth hormone as well as adults suffering from growth hormone deficiency.
Swissmed offers in-licensing development of generic pharmaceuticals in our
R&D Center as well as outsourcing of full size commercial batch production.
In addition our regulatory affairs team is able to compile technical data as
per country specific dossiers and may assist in carrying out bioequivalence
studies through relevant clinical research organizations as per required
guidelines. Further, we have the capability of manufacturing final dosage
forms in country specific GMP approved facilities.